Search

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot

• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot

Getting INSPIRED about improving care for people living with Chronic Obstructive Pulmonary Disease (COPD)

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.

Boehringer Ingelheim - Value Through Innovation

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Hypertension

France

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

Diabetes

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

Scleroderma

Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs

stargardt-disease-infographic

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Human Health Partnering

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

Science Stories

Science and Innovation - Human Health Innovation - Science Stories

Equine asthma: Recognizing and managing respiratory issues in horses

Science Focus

Science and Innovation - Human Health Innovation - Science Focus

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot

Getting INSPIRED about improving care for people living with Chronic Obstructive Pulmonary Disease (COPD)

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Boehringer Ingelheim - Value Through Innovation

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Hypertension

France

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

Diabetes

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

Scleroderma

stargardt-disease-infographic

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Human Health Partnering

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

Science Stories

Equine asthma: Recognizing and managing respiratory issues in horses

Science Focus

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 